Association of glycated hemoglobin A_1c levels with cardiovascular outcomes in the general population: results from the BiomarCaRE (Biomarker for Cardiovascular Risk Assessment in Europe) consortium.

ABSTRACT:

Background

Biomarkers may contribute to improved cardiovascular risk estimation. Glycated hemoglobin A_1c (HbA_1c) is used to monitor the quality of diabetes treatment. Its strength of association with cardiovascular outcomes in the general population remains uncertain. This study aims to assess the association of HbA_1c with cardiovascular outcomes in the general population.

Methods

Data from six prospective population-based cohort studies across Europe comprising 36,180 participants were analyzed. HbA_1c was evaluated in conjunction with classical cardiovascular risk factors (CVRFs) for association with cardiovascular mortality, cardiovascular disease (CVD) incidence, and overall mortality in subjects without diabetes (N = 32,496) an

SUBMITTER: Sinning C 

PROVIDER: S-EPMC8594211 | biostudies-literature | 2021 Nov

REPOSITORIES: biostudies-literature